Skip to content
Screener

Biohaven BHVN Business Segments — Non-operating income

Similar metrics at other companies

NSA
NSAReportable Segment — Non-operating (expense) income
-$302K-184%
Concentrix Corporation logo
CNXCReportable Segment — Other Operating Income
-$42.13M-299%
California Resources logo
CRCTotal Reportable Segments — Other non-operating income, net
$0
Anterix logo
ATEXReportable Segment — Other income
$75K+87.5%
Utz Brands logo
UTZReportable Segment — Other income
$800K+100%
GCM Grosvenor Inc. logo
GCMGReportable Segment — Other income
$1.34M+58.4%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.17B+41.2%
Enterprise value$2.18B+31.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
G&A personnel expense (excluding share-based compensation)(1)5,4556,474
G&A Share-based compensation expense9,81117,829
Other segment items (2)14,45516,951
Non-operating income(168)(493)
Provision for income taxes272609
Segment net loss130,532221,677
Reconciliation of profit or loss
Adjustments and reconciling items

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's business segments — non-operating income?
Biohaven (BHVN) reported business segments — non-operating income of -$168K in Q1 2026.
How has Biohaven's business segments — non-operating income changed year-over-year?
Biohaven's business segments — non-operating income increased by 65.9% year-over-year, from -$493K to -$168K.
What is the long-term trend for Biohaven's business segments — non-operating income?
Over 2 years (2022 to 2024), Biohaven's business segments — non-operating income has grown at a 354.4% compound annual growth rate (CAGR), from $1.91M to -$39.42M.
What does business segments — non-operating income mean?
Includes financial gains or losses derived from activities outside of the company's core biopharmaceutical operations, such as interest income or investment returns. This metric provides a view of the segment's secondary revenue streams and financial management performance. It is important for assessing the overall financial health beyond core drug development.

Ask your AI about Biohaven's business segments — non-operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude